ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$374.47
5.31 (1.44%)
▲
5d:
+7.77%
30d:
+14.6%
90d:
+20.95%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ONC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ONC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$500.66
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$310.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $374.47, which is considered extended relative to its 30-day fair value range of $315.75 to $358.51. The stock's valuation (Forward PE: 36.4) is in line with its historical norms (37.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 166.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a uptrend. The price is approaching resistance at $379.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $433.02 (+15.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONC is in a uptrend. The price is approaching resistance at $379.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $433.02 (+15.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$315.75 -
$358.51
Company Quality Score
27/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.2%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($433.02)
- WARNING: Composite score 27/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$315.75 -
$358.51
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$343.50
Resistance Level
$379.48
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
36.41
Wall Street Target
$433.02
(+15.6%)
Revenue Growth (YoY)
29.6%
Earnings Growth (YoY)
166.7%
Profit Margin
10.7%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
36.4 vs 37.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$371.47
(-1%)
2-Year Target
$368.50
(-2%)
3-Year Target
$365.55
(-2%)
3-Yr Target (if PE normalizes)
(PE: 36→37)
$374.46
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 36.4, Growth: 35.4%)
$928.67
(+148%)
Base:
(SPY PE: 20.1, Growth: 35.4%)
$511.86
(+37%)
Bear:
(PE: 17.1, Growth: 35.4%)
$435.08
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (49x PE), but valuation improves significantly next year (36x PE) as earnings recover.
Forward PE: 48.78 | Forward EPS (Implied): $7.68
Bull Case
$452.17
(+21%)
Analyst growth 15.0%, PE expands to 51.2
Base Case
$374.47
(0%)
Market implied 0.0%, PE stable at 48.8
Bear Case
$286.47
(-24%)
Severe decline -15.0%, PE contracts to 43.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 36.4 to 37.3
Stabilization Target:
$383.59
(+2.4%)
PE Expansion Potential:
+2.4%
Share & Embed Analysis
Last updated: August 23, 2026 3:39 PM ET
Data refreshes hourly during market hours. Next update: 4:39 PM
Data refreshes hourly during market hours. Next update: 4:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |